Cripe Linda H, Barber Brent J, Spicer Robert L, Wong Brenda L, Weidner Norbert, Benson D Woodrow, Markham Larry W
Division of Cardiology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA.
Neuromuscul Disord. 2006 Nov;16(11):745-8. doi: 10.1016/j.nmd.2006.07.021. Epub 2006 Sep 26.
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option.
我们报告了使用持续静脉输注正性肌力药物作为一种姑息治疗策略，用于治疗杜氏肌营养不良症患者有症状的、难治性终末期心脏功能障碍。对3例患有杜氏肌营养不良症和严重扩张型心肌病的患者持续静脉输注米力农和/或多巴酚丁胺，在长达30个月的时间里提供了症状性和客观性的心血管改善。当心脏移植不可行时，持续静脉输注正性肌力药物应被视为杜氏肌营养不良症患者终末期心脏功能障碍的一种切实可行的治疗策略。
